Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Shuttle Pharmaceuticals Holdings, Inc.
Next earnings ≈ Jun 29, 2026 · est. from filing cadence
Last earnings -2.7% on 2026-02-17
Mixed signals in the latest filings.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Shuttle Pharmaceuticals Holdings, Inc. shows limited reported revenue, and -519.9% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001757499, latest 10-Q filed 2026-05-15) · EODHD · rules-based read · as of 6/18/2026, 1:13:27 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$1.74M | -$2.55M | -$5.89M | -$7.70M | -$11.9M |
| Net income | -$1.15M | -$3.03M | -$6.59M | -$9.14M | -$11.7M |
| Diluted EPS | — | -$0.29 | -$3.53 | -$82.60 | -$7.16 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
| 2024-05-01 | Jung Mira Chief Scientific Officer | Award | 598.00 @ $11.28 | $6.75K |
| 2024-03-08 | Vander Hoek Michael Chief Financial Officer | Award | 100K | |
| 2022-12-29 | Senanayake Chris Director | Sell | 1.63K @ $1.61 | $2.61K |